Statin evidence changes with age, risk and prevention setting

The bottom line

PROSPER's combined primary- and secondary-prevention population had fewer coronary death, nonfatal heart attack and stroke events with pravastatin: 408 versus 473, hazard ratio 0.85. The difference was driven by coronary outcomes; stroke was neutral, hazard ratio 1.03. (PROSPER)

But among participants without prior vascular disease, the subgroup result was 11.4% versus 12.1%, hazard ratio 0.94 with a 95% confidence interval of 0.77–1.15. That neutral subgroup must be presented separately from the overall mixed-population result.

Why this matters

“Do statins work in older adults?” hides several different questions. Preventing another event after heart attack, stroke or established arterial disease is secondary prevention. Starting treatment in someone without known vascular disease is primary prevention. Age, frailty, baseline risk, competing illness, treatment horizon and personal priorities can change the likely balance.

A class-level statement built largely from younger people or secondary prevention cannot automatically settle initiation after age 75. Conversely, uncertainty in that narrower setting does not erase evidence for people with established vascular disease.

What researchers did

PROSPER randomized 5,804 adults aged 70–82 with existing vascular disease or risk factors to pravastatin 40 mg daily or placebo for an average of 3.2 years. The trial deliberately mixed primary and secondary prevention, making the overall result useful but not sufficient for either group by itself.

ALLHAT-LLT later provided an older-adult primary-prevention analysis, though crossover and a modest difference in achieved LDL cholesterol weakened its ability to detect an effect. The Cholesterol Treatment Trialists' Collaboration pooled individual participant data from 28 randomized trials to examine how effects changed with age and prior vascular disease.

STAREE and PREVENTABLE were designed to address outcomes important to older adults without established cardiovascular disease. Their registry listings were checked for status and posted results; neither supplied efficacy results at verification.

What they found

PROSPER lowered its overall composite primarily through fewer coronary events, not fewer strokes. It did not show lower all-cause mortality or establish longer life. Its dedicated cognitive analysis found no significant effect on the tested cognitive measures. (Cognition analysis)

The original report noted more new cancer diagnoses with pravastatin. Extended follow-up did not support a persistent excess: the combined cancer hazard ratio was 1.08, p=0.22. That follow-up is important counterevidence and should travel with the initial signal. (Extended follow-up)

Across randomized statin trials, the CTT analysis found fewer major vascular events across age groups. Evidence remained clearer in older people with prior vascular disease; direct evidence was less certain among those older than 75 without it. (CTT meta-analysis)

How strong is the evidence?

Randomization strongly supports PROSPER's overall comparison, but its mixed population and neutral primary-prevention subgroup limit a simple answer about starting treatment in later life. Subgroups are less precise than the full trial. ALLHAT-LLT's crossover and small LDL separation add uncertainty rather than proving no benefit.

Individual-participant meta-analysis increases statistical power and helps show age patterns, yet still depends on the populations and questions represented in the contributing trials. Dedicated trials matter because older adults may value disability-free survival and cognition as much as a composite cardiovascular endpoint.

What this evidence does not show

The featured evidence does not show that everyone over 75 should start, stop or change a statin. It does not choose a medicine or dose, calculate an individual's cardiovascular risk, or resolve how frailty, medication burden, side effects and life expectancy should be weighed in care.

PROSPER did not establish improved cognition, less disability, lower all-cause mortality or longer lifespan. A registry entry for STAREE or PREVENTABLE describes a planned or ongoing study; it is not evidence that the intervention works.

Safety and conflicts

This article does not create a universal statin side-effect estimate because medicines, doses, ascertainment and populations differ. The initial PROSPER cancer imbalance did not persist in longer follow-up, while individual muscle, liver, glucose, interaction and tolerability questions require clinical context.

PROSPER was sponsored and funded by Bristol-Myers Squibb. The publication reported extensive investigator consulting, honoraria, grant and advisory relationships. Publicly funded and independently analyzed evidence adds context but does not make each population interchangeable.

What happens next

STAREE and PREVENTABLE were built to measure outcomes such as disability-free survival, cognition and cardiovascular events in older primary-prevention populations. Until peer-reviewed results are available, they define an evidence gap rather than fill it. Release review must recheck both registries because operational status can change.